Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Active Not Recruiting NCT05712746

Samtasu Post-marketing General Drug Use-results Survey in Patients With Volume Overload in Heart Failure.

Conditions: Heart Failure

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 1600
Sponsor: Otsuka Pharmaceutical Co., Ltd.

Location: Pharmacovigilance Department Osaka

Summary

To confirm the safety of tolvaptan sodium phosphate in patients with volume overload in heart failure.

Eligibility Criteria

Inclusion Criteria: \- Exclusion Criteria: * patients with a known hypersensitivity to Tolvaptan sodium phosphate or Tolvaptan

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05712746). StuddyBuddy aggregates publicly available trial information.